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ABSTRACT 
DESIGNING A PORE-FORMING TOXIN CYTOLYSIN A (CLYA) TO TARGET 
CANCER CELLS 
 
SEPTEMBER 2014 
ALZIRA R.M. AVELINO, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST  
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Min Chen 
Cytolysin A (ClyA) is a member of a class of proteins called pore-forming toxins 
(PFTs). ClyA is secreted by Gram-negative bacteria, and it attacks a number of 
mammalian cells by inserting into and forming channels within the cell 
membrane (Oscarsson J et al., 1999). It has been suggested that ClyA binds to 
cholesterol (Oscarsson J et al., 1999) and thus can insert into the membranes of 
many different cell types of eukaryotic origin.  In our studies we propose to 
engineer a ClyA protein that can only attack a small subset of cell types.  We 
propose to engineer ClyA that can be only activated when exposed to specific 
cell-surface proteases produced by a specific cell type. We ultimately want to 
target breast cancer cells that differentially secrete or express proteases such as 
matrix-metalloproteases (Stautz D et al., 2012; Zhang, M et al. 2013). To 
engineer this protein we took advantage of the N-terminus of ClyA. The N-
terminus of ClyA, which is highly hydrophobic (Oscarsson J et al), undergoes a 
conformational change to insert into the target cell membrane (Oscarsson J et 
al). This conformational change allows ClyA to penetrate the target membrane 
vi	  	  
to form a transmembrane domain of ClyA. The hydrophobic nature of lipid 
membranes makes it highly unfavorable for any charged residues to cross the 
membrane (Hunt J 1997). With this in mind, we hypothesize that negative 
charges inserted into the N-terminus of ClyA will inhibit it from inserting into the 
membrane. Thus, we mutated the N-terminus of the ClyA protein by inserting an 
inactivation site composed of negatively charged amino acids that we 
hypothesize would prevent insertion into the plasma membrane of the target 
cell. Once we confirmed that this construct was an inactive ClyA mutant, we 
inserted a thrombin cleavage site right after the inserted negative charges. This 
site should allow us to remove the negative charges once the protein is exposed 
to thrombin. Once the negative charges are removed, the protein should recover 
its activity. This approach will allow us to create a version of ClyA that is 
protease-switchable
vii	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CHAPTER 1 
INTRODUCTION  
1.1 Cytolysin A (ClyA) as a potential cancer therapeutic 
Finding new treatments for cancer has been one of the top priorities of many 
research laboratories. There have been many treatments such as chemotherapy 
and radiation therapy that have been shown to be effective. However, these 
treatments have many side effects. These treatments often attack rapidly 
replicating cells in a non-specific manner, and there is always a chance of 
disease reoccurrence. For this reason it is necessary to develop new treatments 
that are more effective and specific (Hassan et al., 2010).  
New developments combine current therapies with bacterial therapy (BT). 
Studies have shown that bacteria such as Escherichia coli (E. coli) accumulate in 
tumors (Chen D et al, 2010; Kim J. et al. 2008; Anderson, J. C. et al. 2006), and 
we can use this characteristic to deliver specific anti-tumor treatments. 
1.2 Cytolysin A (ClyA) 
Cytolysin A (ClyA) is a pore-forming protein secreted by Gram-negative bacteria 
such as E. coli and Salmonella enterica, serova, typhi and Paratyphi A (Jiang S. 
et al., 2010; Von Rhein, C. et al, 2009).  The shape of ClyA is a long rod, and it is 
comprised of 81% α-helices and 2% β strands (Wallace et al., 2000). It is a 34 
kDa protein that is cytotoxic to cultured mammalian cells and can also cause 
macrophage apoptosis (Jiang S., 2010). ClyA is transported from the bacteria to 
the target cell in outer membrane vesicles (OMVs) as an oligomer (Chen et. al, 
2	  	  
2008). Once ClyA reaches the target membrane, the N-terminus (Figure 1a in 
red) undergoes a conformational change and inserts into the membrane (Figure 
1b). ClyA is made as a soluble monomer and exported to the periplasm (Chen et. 
al, 2008).  To form into an active pore, the protein oligomerizes into a dodecamer 
Chen et. al, 2008) (Figure 1b) that has a diameter of 35 Å at its narrowest 
opening and 70 Å at the top of the oligomer (Mueller M. et al., 2009). The X-ray 
crystal structure of the monomer was solved by Wallace et al. (Wallace AJ. et al 
2000 Cell), and the oligomer crystal structure was solved by Mueller et al. 
(Mueller M. et al., 2009).   	  a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  b)	  	  
	   	  	  
	  
	  
Figure 1: Schematic representation of ClyA molecules.  (a) Representation 
of an inactive monomer, with the N-terminus tucked in; (b) The active protomer 
with the N-terminus inserted into a target lipid membrane. In a and b, the N-
terminus is highlighted in red. Structures were drawn in PyMol. 
 
The toxic ClyA pore shown in Figure 1b promotes lysis of the target cell by 
allowing uncontrollable exchange of materials between the extracellular 
environment and the intracellular contents.
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CHAPTER 2 
RESULTS AND DISCUSSION 
2.1 Construct design  
To make a switchable form of ClyA, we took advantage of its N-terminus, 
which is responsible for its membrane insertion. The N-terminus of ClyA crosses 
the target lipid membrane and forms a transmembrane domain. By mutating the 
N-terminus, we can prevent the membrane insertion.  
Charged residues are very energetically unfavorable to cross the cell 
membrane (Hunt J 1997). Moreover, we hypothesize that negative charges are 
even more unfavorable because the phospholipid heads that are also negatively 
charged should repel the negative residues on ClyA. Therefore, we hypothesized 
that negative charges added to the N-terminus will inhibit ClyA insertion into a 
target membrane.  
To accomplish this, we designed mutant ClyA proteins that contain 
stretches of negatively charged amino acids (aspartate and/or glutamate) and 
tested the activity of these modified proteins with hemolytic assays, where we 
mix the ClyA proteins with erythrocytes and if lysis occurs hemoglobin is released 
and quantified with the use of a spectrophotometer (540 nm). For more detail, 
refer to Appendix A. Initially our constructs contained negative charges added at 
the N-terminus and a hexa-histidine tag (His-tag) at the C-terminus. Later, the 
His-tag was moved from the C-terminus to the N-terminus in modified constructs.  
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To make the mutant ClyA a switchable protein, we also designed constructs with 
a protease (thrombin) cleavage site directly after the negative charges. If 
exposed to protease (thrombin), the negatively charged amino acids could then 
be cleaved off and the ClyA protein reactivated. Figure 2 summarizes the 
designed constructs.  
 
Figure 2: Protein representation of the designed mutant versions of ClyA.  
The figure above describes the location of the inactivating site (red), comprised of 
varying numbers of aspartates (Asp) and/or glutamates (Glu), the His-tag (blue) 
and the thrombin cleavage site (yellow). ClyA is indicated in gradient black. 
 
2.2 Purification of the inactive mutant proteins 
All of the constructs were purified using nitrilotriacetic acid affinity 
chromatography (Ni-NTA) purification, which takes advantage of specific binding 
between the His-tag and nickel immobilized in the chromatography column 
(Figure 3). To further purify ClyA, we used gel filtration chromatography (GFC) 
that separated molecules according to their stochastic radius. Whereas a 
monomer of ClyA will elute with buffer at a volume of 15 ml using Superdex 200, 
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the mutant proteins elute at 17 ml of retention volume (Fig. 4). For more 
information on this technique, refer to Appendix A.  
	  
Figure 3: Nickel affinity chromatography of His-tagged ClyA. Graph in black 
represents absorbance of protein at 280 nm and the graph in red is the 
percentage of 0.5 M imidazole in the elution buffer. ClyA starts to elute at just 
under 20% 0.5 M imidazole. The light blue bar represents where the ClyA 
monomer was collected. 
	  
Figure 4: Gel filtration chromatogram of ClyA monomer. The pure, negatively 
charged ClyA mutants elute around 17 ml. The red bar represents where the 
ClyA monomer was collected. 
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2.3 Testing the activity of purified samples   
 
To test the activity of the ClyA putatively inactive mutants, we use a liquid 
hemolytic assay (Fahie, M. et al. 2013; Rowe, G. C. et al.1994). ClyA can lyse 
erythrocytes, thus releasing hemoglobin that can be quantified by measuring its 
innate absorbance at 540 nm (Iwasaka, M., et al. 2001). The absorbance value 
and the release of hemoglobin directly correlate with the number of erythrocytes 
lysed and thus how active the protein (ClyA) is. Refer to Appendix A for details on 
how the experiment was performed. 
Figure 5 below shows the activity of the mutant ClyA using construct 1 
from Figure 2, with different numbers of negative charges. At 6, 10, 12, 15, or 18 
negative charges (aspartates and glutamates) the activity of ClyA was not 
completely inhibited, as indicated by 60% lysis or higher.  These findings led us 
to increase the number of negative charges up to 24 (Figures 5 and 6). 
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Figure 5: Hemolytic activity of ClyA mutants. Constructs with increasing 
numbers of negative charges (6-cyan,10-blue,12-navy,15-gray,18-black) 
designed from construct 1 (Figure 2) were tested. All samples had a protein 
concentration of 0.7 μg/ml. From the above figures, we can see how various 
numbers of negative charges affect the activity of ClyA. All samples were 
incubated with defibrinated sheep red blood cells at 370C for 15 minutes. WT: 
wild-type ClyA, without additional negative charges.  
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Figure 6: Hemolytic activity of mutant ClyA proteins with larger numbers of 
negative charges.  Twenty-one negative charges (cyan) and 24 negative 
charges (dark blue) from construct 1 (Figure 2) and WT ClyA (white) with a C-
terminal His-tag were tested. All samples had a protein concentration of 0.6 
μg/ml. From the above figures we can see how various numbers of negative 
charges affect the activity of ClyA. All samples were incubated with defibrinated 
sheep red blood cells at 370C for 15 minutes. 
 
 Even with increasing numbers of negative amino acids, the activity of ClyA 
was still very high. This result suggests that either 24 negative charges can 
comfortably cross a bilayer, or that we are not working with the expected 
construct.  However, as mentioned earlier, it is highly unfavorably to insert 24 
negative charges across a bilayer (Hunt J 1997). To distinguish between the 
possible explanations, we moved the His-tag from the C-terminus to the N-
terminus directly before the negative charges (construct 2, Figure 2). This allows 
only the correct mutant protein to be selected by nickel affinity purification.   
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Figure 7 below shows the activity of the mutant ClyA with different 
numbers of negative charges and with an N-terminal His-tag (Nhis). 
	    
Figure 7: Hemolytic activity of mutant ClyA proteins with different numbers 
of negative charges and an N-terminal His-tag. 6-Nhis is ClyA with six 
additional negative charges and an N-terminal His-tag, 12-Nhis has 12 negative 
charges and an N-terminal His-tag, and 18-Nhis has 18 negative charges and an 
N-terminal His-tag. All samples had a protein concentration of 4.4 μg/ml. The 
negative control in black contains blood with no protein added. From the above 
figure we can see how much each number of negative charges with an N-
terminal His-tag affected the activity of ClyA. All samples were incubated with 
defibrinated sheep red blood cells at 370C for 15 minutes. 
	  
The hemolytic assay shows that with 12 and 18 negative charges after the 
N-terminal His-tag, the activity of ClyA is increasingly inhibited. Because of this 
result, we concluded that the mutants based on construct 1 were being post-
translationally cleaved to wild type (WT)-like-ClyA.   
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2.4 Making a switchable ClyA 
 The next step is to introduce a thrombin cleavage site just after the 
negative charges so that when thrombin is present it can cleave the negative 
charges, thus reactivating ClyA (construct 3, Figure 2). 
After purification with GFC and confirming that we had obtained the pure 
mutant protein by performing sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Figure 8), the new mutant protein with the 
thrombin cleavage site and 18 negative charges (18-NhisT) was incubated with 
thrombin in a cleavage assay and its activity tested (Figure 9). For more 
information on the thrombin cleavage assay see Appendix A. The expected size 
of ClyA is 34 kDa. However, the mutants with N-terminal negative charges seem 
to travel further down the SDS-PAGE gel. We hypothesize that the negative 
charges may be the cause of this migration pattern, since the additional negative 
charges in the mutant proteins may make them more strongly attracted to the 
positive electrode during SDS-PAGE (Figure 8). The WT ClyA band intensity is 
stronger than the band intensities for the negative mutants, because the 
purification with nickel columns yields a lower concentration of negative mutant.   
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Figure 8: SDS-PAGE of purified proteins after GFC. 18-Thr-ClyA is the mutant 
ClyA with 18 negative charges, thrombin cleavage site and N-terminal His-tag. 
18-ClyA lacks the thrombin cleavage site. WTClyA has an N-terminal His-tag, but 
no additional negatively charged residues. 
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  Figure 9: Hemolytic assay of the mutant 18-thr-ClyA protein with N-terminal 
His-tag. One mole of wild-type or mutant ClyA (18-NhisT) was incubated with 2.5 
moles of thrombin overnight at room temperature. All samples had a protein 
concentration of 4.4 μg/ml. Then the samples were incubated with red blood cells 
for 15 minutes at 370C to test for hemolytic activity (WTClyA Nhis-tag in gray, 18-
thr-ClyA in white with vertical stripes. 18-thr-ClyA in black indicates the mutant 
with no thrombin added, and the cyan bar represents thrombin incubated with 
blood with no other protein added). 
 
The activity assay of Fig. 9 showed that thrombin treatment did not restore 
the mutant’s activity, leading us to question whether the thrombin site was 
accessible to thrombin. Thus, we inserted a longer glycine linker between the 
inactivating site and the cleavage site (Figure 2, construct 3); the insertion of this 
type of linker has been shown to improve the cleavage site’s accessibility to 
thrombin (Hakes, D. et al, 1992).     
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After obtaining and purifying the constructs with longer G-linkers (from 1 
glycine to 6 glycines) named 12-NhisT and 18-NhisT (construct 3, Figure 2), the 
hemolytic activity of the constructs was once again tested after incubation without 
and with thrombin (Fig. 10).  
	  	  
Figure 10: Hemolytic assay of 12-NhisT and 18-NhisT with a hexa-glycine 
linker. The samples were incubated with thrombin in a 1:3.5 molar ratio 
overnight at room temperature. Then the samples were incubated with red blood 
cells for 15 minutes at 37°C. The concentration of protein present in all the 
samples was 10.5 μg/ml. The negative control in white just contains erythrocytes 
in buffer with no added protein. WTNhis ClyA in black is the positive control; 12-
NhisT in dark gray with oblique strips is the ClyA mutant with 12 negative 
charges, thrombin cleavage site and N-terminal His-tag. 18-NhisT differs from the 
previous construct (12-NhisT) only in the fact that it contains 18 N-terminal 
negative charges. 
 
  From Figure 10, we conclude that the longer glycine linker has improved 
the accessibility of the cleavage site to thrombin, because when these ClyA 
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mutant proteins were incubated with thrombin, the percent of lysis had a 30% 
increase for 18-NhisT, and for 12-NhisT to almost WT status. Although after 
thrombin treatment 12-NhisT2 regained high activity, this protein is still active 
(~24% lysis) when thrombin is not present.  Ideally, we want to design a 
switchable ClyA that is completely inactive without thrombin treatment even at 
high protein concentrations of the ClyA construct, which is the case for 18-NhisT. 
This latter mutant has very low activity, approximately 2%, in the absence of 
thrombin, but when thrombin is present the hemolytic activity of 18-NhisT 
increases to approximately 30%. However this activity increase is still not ideal. 
Ideally we would want a hemolytic activity increase to 80% or more. A shorter 
incubation period at 37°C would also be preferable (4 hours or less) and a molar 
ratio of at least 30:1 (ClyA protein to thrombin) is more desirable for medical 
application. We ultimately want to be able to activate the switchable protein in a 
short period of time and with a low concentration of protease, which we 
hypothesize would mimic human biological conditions.  
 In this matter, new constructs are being designed in order to increase 
activity when a specific protease is present and also to retain inactivity when the 
specific protease is absent. Once the new constructs are tested and satisfy all of 
these requirements, we will proceed to the next steps, which will be to design 
metalloprotease cleavage sites into the optimal construct and perform activity 
experiments with cultured mammalian cell lines.   
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2.5 Mechanism of inhibition 
We hypothesized that adding negative charges inhibits membrane 
interaction, but activity can also be inhibited by preventing the oligomerization of 
ClyA. The lack of activity of the mutant 18-Nhis could be due to an inefficient 
membrane insertion or inefficient oligomerization, since the negative charges on 
individual monomers may not only repel the phospholipid bilayer but also repel 
each other. To test whether oligomerization was inhibited, we induced 
oligomerization with the commonly used detergent n-dodecyl-ß-D-
maltoside (DDM). We used GFC to detect the various oligomerization states (see 
Appendix A). According to the elution pattern, we can determine whether ClyA is 
oligomerized or not. Elution of the protein earlier than 17 ml means that the 
mutant can oligomerize into various forms such as dimers, etc., but if 
oligomerization is disrupted, the protein will elute as a monomer around 15 ml or 
17ml depending on whether it is a WT or mutant ClyA, respectively. 
 The mutant used for the oligomerization assay is 18-thr-ClyA (construct 3, 
Figure 2). This mutant has 18 negative charges at its N-terminus and additionally 
a thrombin cleavage site immediately after the negatively charged region.  
Figure 11 shows GFC chromatograms of the elutions of the mutant (18-
thr-ClyA) and WT with the N-His-tag. 
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Figure 11: GFC chromatograms of elutions of the different mutant proteins 
with and without 0.1% DDM. After incubation with 0.1% DDM, the different 
samples indicated above were run through GFC in buffer containing 0.01% DDM. 
a) represents WT ClyA with no DDM added, b) shows the mutant with the 18 
negative charges and N-His-tag with no DDM added. c) represents WT ClyA with 
0.1% DDM added and incubated at 23°C for 30 minutes prior injection onto GFC, 
and d) represents the 18-thr-ClyA mutant with the N-His tag prepared the same 
way as in graph c. The y-axis represents absorbance at 280 nm (wavelength at 
which protein absorbs light); the x-axis indicates the retention volume in ml.  
 
 
 According to Figure 11, the mutant 18Nhis cannot oligomerize into a 
stable dodecamer (chromatogram d), because it still elutes after 15 ml of 
acquired volume. The WTNhis ClyA forms stable oligomers when incubated with 
0.1% DDM at 23°C and elutes as a monomer when not incubated with DDM (Fig. 
11a).  
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 According to the data obtained thus far, we can conclude first that 18 
negative charges at the N-terminus inhibit ClyA activity by inhibiting 
oligomerization and second that thrombin cleavage with the optimized linker 
restores the activity of this mutant. Further research is being performed in order 
to optimize the percent recovery when appropriate protease is added. 
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APPENDIX A 
MATERIALS AND METHODS 
Cloning strategy 
All chemicals used were purchased from Fisher Scientific (Agawam, MA) unless 
specified otherwise. 
The negative mutants ClyA were cloned and amplified in a pT7 vector with a C-
terminal or N-terminal His-tag.  The polymerase chain reaction (PCR) was 
performed using Phusion Polymerase (New England Biolabs, Ipswich, MA). The 
PCR products were digested with DpnI to degrade the template DNA. The 
digestion was performed for 3 hours at 37°C or overnight at the same 
temperature.  The DpnI product was then transformed into Escherichia coli (E. 
coli) Nova Blue cells. The DNA sequence of the desired products was obtained 
through DNA sequencing from the Genomics & Bioinformatics Facility (University 
of Massachusetts Amherst, Amherst, MA).  Refer to Table 1, Appendix B for the 
list of primers and templates used. 
Protein expression 
To obtain the desired protein, we inoculated E. coli BL21 cells containing 
the plasmid pT7-ClyA with the specific mutation into 1 L of Luria Broth (LB) 
medium (Boston Bioproducts, Ashland, MA) containing 0.1 mg/ml of ampicillin. 
The cells were grown at 37°C with shaking at 200 rpm to an OD600 of 0.6. Then 
0.5 mM of Isopropyl β-D-1-thiogalactopyranoside was added to induce protein 
expression. The culture was incubated overnight at 15°C.  
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Protein purification 
After expression, the cell culture was spun down for 30 minutes at 4000 
rpm in a tabletop centrifuge. The supernatant was discarded and the pellet was 
resuspended in 20 ml of 50 mM Tris-HCl, pH 8, 0.2 mg/ml lysozyme, 1 mM 
ethylenediaminetetraacetic acid- EDTA, and 0.1 mM 
phenylmethanesulfonylflouride (Sigma, St. Louis, MO). Then the lysate was 
incubated for 30 minutes on ice. The lysate was then spun down for 30 minutes 
at 13,000 rpm in a Sorvall RC 6 Plus centrifuge from Thermo Scientific (Waltham, 
MA).  The supernatant then was used for the following techniques.  
The ClyA purification involves two chromatographic techniques: Ni-NTA 
purification and gel filtration chromatography (GFC). For Ni-NTA purification, a 
His-tag is introduced at the N-terminus or C-terminus of the protein. To do the 
nickel purification, we used a column packed with beads that contain nickel 
(Pierce centrifuge column, gravity column, from Thermo Scientific, Waltham, MA). 
This column has a total volume of 4 ml. At the start of purification the column is 
washed with 2 column volumes (CV) of 20% ethanol, 2 CV of miliQ water and 2 
CV of Buffer A (150 mM NaCl, 50 mM Tris-HCl, pH 8). Tris was purchased from 
Boston Bioproducts (Ashland, MA). After equilibrating the column with Buffer A, 
the cell lysate is added and incubated with the nickel beads for 15 minutes on ice 
with shaking. Then the lysate is allowed to pass through the column at a rate of 
10 drops per minute. The rate can be controlled by capping the column, reducing 
or increasing the airflow through the column. Only after the cell lysate has 
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completely run through is 1 CV of Buffer A added to wash off unbound proteins. 
Two more washing steps are conducted with Buffer A’ (150 mM NaCl, 50 mM 
Tris-HCl, pH 8 and 10 mM imidazole from Thermo GE Healthcare) and Buffer A1 
(150 mM NaCl, 50 mM Tris-HCl, pH 8 and 25 mM imidazole). Imidazole will 
displace the protein of interest, which is collected in fractions.  All fractions are 
collected and run on a15% SDS-PAGE gel, containing 2,2,2-Trichloroethanol 
(TCE), to determine which fraction has a higher concentration of pure ClyA using 
the Gel DocTM imager from Bio RAD (Hercules, CA). The fraction with pure ClyA 
is then dialyzed overnight (dialysis membrane from Spectra/Pro, MW cutoff 6-
8000) in Buffer A (with EDTA) at 4°C. The second part of the purification involves 
purification by GFC which separates proteins according to their stochastic radius. 
For this type of chromatography we use the Superdex 200 column from CE 
Healthcare (Piscataway, NJ). The column has a volume of 24 ml and elutes 
soluble WT ClyA monomers at a 15 ml retention volume and elutes the 
negatively charged mutants at a 17 ml retention volume. Initially the column is 
washed with 2 CV of 20% ethanol and 2 CV of water, and then the column is 
equilibrated with 2 CV of Buffer A. The dialyzed protein sample is concentrated to 
1 ml using a Centricon from Millipore (Billerica, MA). Then the sample is injected 
into the equilibrated column. Fractions are collected at the appropriate retention 
volume and analyzed by SDS-PAGE (Figure 8) to determine the purity of the 
sample. The protein concentration is determined with a Bicinchoninic acid (BCA) 
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assay (kit from Thermo Scientific, Waltham, MA), and samples are stored at a 
temperature of -80°C.  
Hemolytic assay 
To perform the hemolytic assays, we use defribinated sheep blood from Lampire 
Biological Laboratories (Pipersville, PA). The blood is washed with milliQ water 
containing 150 mM NaCl and centrifuged in a tabletop centrifuge from Eppendorf 
(4,000 rpm, for 5 minutes) to pellet the red blood cells, the supernatant is 
discarded, and the blood is diluted to 25% with milliQ water containing 150 mM 
NaCl. There are two main controls for this experiment (positive and negative 
control). The negative control is blood with buffer but no protein added, and the 
positive control is 25% blood plus milliQ water brought up to the same volume 
used in other samples. Twenty five percent blood is added to each sample and 
the final volume of the protein solution depends on the desired protein 
concentration (indicated in Figures 5, 6, 7, 9, and 10). The samples are incubated 
at 37°C for 15 minutes; then the samples are centrifuged in a tabletop centrifuge 
at 14,000 rpm for 2 minutes. The supernatant contains the hemoglobin released 
from the cell, and its absorbance is measured at 540 nm. The absorbance values 
are used to plot a graph indicating the percentage of lysis. The positive control 
indicates 100% lysis while the negative control acts as a baseline for zero lysis.  
Oligomerization assay 
This experiment is performed to determine whether the mutant proteins, like WT 
ClyA, can oligomerize in 0.1% n-Dodecyl β-D-maltoside (DDM). Seventy 
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micrograms of protein is incubated with 0.1% DDM at 23°C (see Figure 7) for 30 
minutes and then injected into the GFC column equilibrated with Buffer A 
containing 0.01% DDM. The elution pattern is observed: if the protein elutes 
before 15 ml of retention volume, it means that the protein can indeed form 
various oligomers. However, if the protein elutes around 15-17 ml, it is eluting as 
a monomer. 
Thrombin cleavage assay 
This assay is performed for mutant proteins that have a thrombin cleavage site. A 
specific concentration of protein (see Figures 5, 6, 7, 9, and 10) is incubated with 
thrombin (in a molar ratio indicated in the figure legend) overnight at room 
temperature (approximately 23°C). After incubation, the samples are subjected to 
a hemolytic assay to test if the activity is recovered. Thrombin is purchased from 
MP Biomedicals (Santa Ana, CA). 
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APPENDIX B 
 
TABLE OF ALL MUTANTS AND PRIMERS 
 
Table 1: List of all the negative mutants and primers used. 
Negativ
e 
mutant 
ClyA 
Primers Templa
te 
Inserted 
amino 
acid 
sequence 
Purpose 
6- F-
GATGATGACGATGACGACACTGA
AATCGTTGCAG 
WT-
ClyA 
C-His 
tag 
 
 
M-D6-ClyA 
Engineered  
6-Aspartate 
tag on  
ClyA at the 
N- terminus 
to  
Inhibit 
membrane 
insertion.   
R- 
GTCATCGTCATCATCCATCTCGA
GAGCCCA TATG 
10- F- 
AGAGGAGGACGACGAAGAAGAT
ACTGAAATCGTTGCAG 
6-  
 
 
M-
E5D2E2D-
ClyA 
Engineered  
6-
Aspartate, 
2- 
Glutamate 
and 2-
Aspartate  
tag on ClyA 
N-terminus 
to  
inhibit 
membrane 
insertion 
R- 
TTCGTCGTCCTCCTCTTCTTCCT
CCATCTCGAGAGCCCATA 
 
12- F- 
GAGGAGGAAGAGGAGACTGAAA
TCGTTGCAG 
 
6-  
M-D6E6-
ClyA 
 
Engineered  
6-Asp, 6-
Glu tag on 
ClyA N-
terminus to 
inhibit  
membrane 
insertion 
R- 
CTCCTCTTCCTCCTCTTCGTCGT
CATCGTC 
15- F- 
GAGGAGGATGACGAGACTGAAA
TCGTTGCAG 
 
12- M-
D6E6D2E-
ClyA 
 
Insertion of 
5 additional 
negative  
charges 
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R- 
GTCTCGTCATCCTCCTCTTCCTC
CTCTTCG 
18- F-
GGATGACGAGGAGGAAGATACT
GAAATCGTTGCAG 
 
15-  
M-D6E6D2E 
3D-ClyA 
Insertion of 
3 additional 
negative  
charges 
R- TAT 
CTTCCTCCTCGTCATCCTCCTCT
T CCTCCTC 
21- F- 
GATGACGATGAAACTGAAATCGT
TGCAGAT 
18-  
M-D6E6D2E 
3D3E-ClyA 
Insertion of 
3 additional 
negative  
charges 
R- 
AGTTTCATCGTCATCTTCCTCCTC
GTC 
24- F- 
ACGATGAAGATGACGAGACTGAA
ATCGTTGCAG 
21- M-
D6E6D2E-C 
3D3ED2E-
ClyA 
 
Insertion of 
3 additional 
negative  
charges 
R- 
GTCTCGTCATCTTCATCGTCATC
TTCCTCCTCGT 
N-his 
tag 
F- 
CACCATCATCACCACCATGATGA
TGACGATGAC  
 
6-, 12-, 
18- 
 
M-H6-
inactive 
site-ClyA 
Insertion of 
an N-
terminal  
His-  
tag 
R- 
CATGGTGGTGATGATGGTGCATC
TCGAG AGCCCA 
Thrombi
n site 
insertion 
12- 
F- 
CCTGGTGCCGCGTGGTAGCACT
GAAATCGTTGCA   
 
12-  
with an 
N-His 
tag 
 
M-H6-D6E6-
GSLVPRS-
ClyA 
Insertion of 
a thrombin  
cleavage 
site 
R- 
CCACGCGGCACCAGGCTGCCCT
CCTCT TCCTCCTCT  
 
Thrombi F- 18- M-H6- Insertion of 
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6-, 10-, 12-, 18-21-, and 24- refers to ClyA mutants with 6, 10, 12, 18, 21, 24 
negative charges at the N-terminus respectively and a C-terminal His-tag. N-His 
tag refers to a Histidine tag at the N-terminal of ClyA. All primer sequences are 
presented from left to right or 5’ to 3’, respectively. The forward (F) and reverse 
(R) primers are depicted above for every negative mutant.  
 
 
 
 
 
 
 
 
 
 
n site 
insertion  
18- 
CCTGGTGCCGCGTGGTAGCACT
GAAATCGTTGCA 
 
with an 
N-His 
tag 
D6E6D2E3D
- 
GSLVPRS-
ClyA 
 
a thrombin  
cleavage 
site 
R-
CCACGCGGCACCAGGCTGCCAT
CTTCCTCCTCGTC  
 
Glycine 
linker 
insertion 
F-
AGCGGTGGCGGTGGTGGCCTGG
TGCCGCGTGGT  
 
12- with 
an  N-
His-tag 
and 
thrombi
n site 
 
18- with 
an N-
His-tag 
and 
thrombi
n site 
M-H6-D6E6-
GSG5SLVP
RS-ClyA 
 
 
M-H6- 
D6E6D2E3D
- 
GSG5SLVP
RS-ClyA 
 
Inserting a 
5-glycine 
linker 
R- 
CAGGCCACCACCGCCACCGCTG
CCCTCCTCTTC  
 
C-
terminal 
His tag 
deletion  
F-
CTCTCGAGATGACTGAAATCGTT
GCAG 
 
6-, 12- 
and 18- 
Not 
applicable 
Deleting the 
C-terminal 
His-tag 
R-
TTTCAGTCATCTCGAGAGCCCAT
ATG 
 
	  26	  
REFERENCES 
 
Anderson, J. C., Clarke, E. J., Arkin, A. P. & Voigt, C. A. Environmentally 
controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 355, 619–
627 (2006). 
 
Chen, D. J, Osterrieder, N., Metzger, S.M., Buckles, E., Doody, A., Putnam D., 
DeLisa M. P. Delivery of foreign antigens by engineered outer membrane vesicle 
vaccines. Proc. Natl. Acad. Sci. U. S. A. 107, 3099–104 (2010). 
 
Fahie, M., Romano, F., Chisholm, C., Heuck, A. P., Zbinden, M., Cehn, Min. A 
non-classical assembly pathway of Escherichia coli pore-forming toxin cytolysin 
A. J. Biol. Chem. 288, 31042–51 (2013). 
 
Hakes, D. J. & Dixon, J. E. New vectors for high level expression of recombinant 
proteins in bacteria. Anal. Biochem. 202, 293–8 (1992). 
 
Hassan, M. S. U., Ansari, J., Spooner, D. & Hussain, S. A. Chemotherapy for 
breast cancer (Review). Oncol. Rep. 24, 1121–1131 (2010). 
 
Hunt, J. F., Rath, P., Rothschild, K. J. & Engelman, D. M. Spontaneous, pH-
dependent membrane insertion of a transbilayer α-helix. Biochemistry 36, 15177–
15192 (1997). 
 
Iwasaka, M., Miyakoshi, J. & Ueno, S. Optical absorbance of hemoglobin and red 
blood cell suspensions under magnetic fields. in IEEE Trans. Magn. 37, 2906–
2908 (2001). 
 
Jiang, S.-N, Phan, T. X., Nam, T., Nguyen, V. H., Kim H., Bom, H., Choy, H. E., 
Hong, Y., Min J.  Inhibition of tumor growth and metastasis by a combination of 
Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol. Ther. 18, 635–
42 (2010). 
 
Kim, J. Y., Doody A. M,  Chen D. J.,  Cremona G. H,  Shuler M. L.,  Putnam D., 
DeLisa M. P. Engineered bacterial outer membrane vesicles with enhanced 
functionality. J. Mol. Biol. 380, 51–66 (2008). 
 
Mueller, M., Grauschopf, U., Maier, T., Glockshuber, R. & Ban, N. The structure 
of a cytolytic alpha-helical toxin pore reveals its assembly mechanism. Nature 
459, 726–730 (2009). 
 
Oscarsson, J., Mizunoe, Y., Li, L., Lai, X. H., Wieslander, a, & Uhlin, B. E. 
Molecular analysis of the cytolytic protein ClyA (SheA) from Escherichia coli. 
Molecular Microbiology, 32(6), 1226–38 (1999).  
	  27	  
 
Rowe, G. E. & Welch, R. A. Assays of hemolytic toxins. Methods Enzymol. 235, 
657–667 (1994). 
Stautz, D., Wewer, U. M. & Kveiborg, M. Functional analysis of a breast cancer-
associated mutation in the intracellular domain of the metalloprotease ADAM12. 
PLoS One 7, (2012). 
 
Von Rhein, C., Bauer S, López Sanjurjo EJ, Benz R, Goebel W, Ludwig A. ClyA 
cytolysin from Salmonella: Distribution within the genus, regulation of expression 
by SlyA, and pore-forming characteristics. Int. J. Med. Microbiol. 299, 21–35 
(2009). 
 
Wallace, A. J., Stillman TJ, Atkins A, Jamieson SJ, Bullough PA, Green 
J, Artymiuk PJ. E. coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of 
the toxin and observation of membrane pores by electron microscopy. Cell 100, 
265–76 (2000). 
  
Zhang, M., Teng, X., Guo, X., Li, Z., Han, J., & Yao, L. Expression of tissue levels 
of matrix metalloproteinases and their inhibitors in breast cancer. Breast 
(Edinburgh, Scotland), 22(3), 330–4 (2013). 
 
 
 
 
 
 
 
 
 
 
  	  
